Attitudes and digital health literacy mediate the relationship of digital information accessibility with intention for digital healthcare service use in patients with multiple myeloma: A cross-sectional study.

Purpose: This study aimed to investigate the serial mediating effects of attitudes toward digital healthcare services (ATDH) and digital health literacy (DHL) on the relationship between accessibility of digital information (ADI) and intention to use digital healthcare services (IUDH) among patients with multiple myeloma (MM).

Methods: A cross-sectional questionnaire-based survey was conducted with patients with MM under outpatient follow-up at the cancer center of a university-affiliated hospital in South Korea. Data were collected between September and December 2023 from a convenience sample of 139 patients.

Silibinin alleviates house dust mite induced allergic airway inflammation by inhibiting NLRC4 inflammasome and MMP-9 expression.

Silibinin, a major compound of silymarin, has been reported to alleviate respiratory diseases including acute lung injury, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis through its antifibrotic, anti-inflammatory, and antioxidant properties. However, the specific mechanisms underlying its therapeutic effects, particularly in allergic asthma, are not fully understood. With the increasing prevalence and impact of allergic asthma, there is a need to elucidate the exact underlying mechanisms of its potential treatment effects.

PD-L1 as a Biomarker in Gastric Cancer Immunotherapy.

Combining chemotherapy with immune checkpoint inhibitors (ICIs) that target the programmed death-1 (PD-1) protein has been shown to be a clinically effective first-line treatment for human epidermal growth factor receptor 2 (HER2)-negative and -positive advanced or metastatic gastric cancer (GC). Currently, PD-1 inhibitors combined with chemotherapy are the standard treatment for patients with HER2-negative/positive locally advanced or metastatic GC. Programmed death-ligand 1 (PD-L1) expression, as assessed using immunohistochemistry (IHC), is a crucial biomarker for predicting response to anti-PD-1/PD-L1 agents in various solid tumors, including GC.